


CLAIMS

1. A composition comprising:

a first compound having the structure of formula (P-II):



wherein:

P-N is a protein agent comprising a lysine residue wherein the protein agent is an IgG antibody;

L^{PM} is a linker, wherein L^{PM} comprises one or more $-[(CH_2)_n-O]_m-$, wherein each n is independently 1-20, and m is 1-100; and

MOI is a therapeutic agent; and

a second compound having the structure:



wherein LG is a group comprising a target binding moiety that binds to a target agent, and the target agent is the IgG antibody, and wherein LG is or includes a target binding moiety that is or comprises DCAWXLGELVWCT (SEQ ID NO:1), wherein the two cysteine residues optionally form a disulfide bond, and X is an amino acid residue.

2. The composition of claim 1, wherein MOI is a moiety that binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is implicated in the Coronavirus Disease 19 (COVID-19).

3. The composition of claim 1, wherein MOI is SEQ ID NO: 2 or SEQ ID NO: 3.


4. The composition of Claim 1, 2 or 3, further comprising:

a third compound having the formula (R-I):



LG is a group comprising a target binding moiety that binds to the protein agent, and is identical to LG in formula (LG-I);

RG is a reactive group, wherein RG is a group of the formula $-L^{LG2}$, $-L^{LG2}-L^{LG3}-L^{LG4}-L^{RG1}-$ or $-L^{RG1}-L^{RG2}-$, wherein



L^{LG3} is an optionally substituted aryl ring;

L^{LG4} is a bond, $-NH-$ or $-O-$;

L^{RG1} is $-O-C(O)-$, $-C(O)-$, $-S(O)-$, $-OS(O)_2-$, or $-OP(O(OR))-$;

L^{RG2} is $-CH_2-C(O)-$, $-C(O)-$, or $-CH_2-$;

L^{RM} is a linker, which is identical to the linker L^{PM} in formula (P-II); and


MOI is a therapeutic agent which is identical to the therapeutic agent of formula (P-II);

a fourth compound having the formula (R-III):



or a combination thereof.



5. The composition of any one of Claims 1 to 4 wherein LG is or comprises a target binding moiety having the structure of formula A-50,




6. The composition of claim 4, wherein:

(a) the reactive group is or comprises $-C(O)-O-$ or $-O-C(O)-$; or.


(b) the reactive group comprises an aryl group, optionally bonded to $-C(O)-O-$ or $-O-C(O)-$ and substituted with one or more electron-withdrawing groups; or

(d) the aryl group has the structure of  or , wherein R^s is independently chosen at each occurrence from halogen, -NO₂, -F, -L-R', -C(O)-L-R', -S(O)-L-R', -S(O)₂-L-R', and -P(O)(-L-R')₂, and R' is H or C₁-C₆alkyl.

7. The composition of any one of claim 1 to 6, wherein RG is a group of the formula -L^{LG2}-L^{LG3}-L^{LG4}-L^{RG1}- and is selected from:



8. The composition of claim 7, wherein RG is:




9. The composition of any one of Claims 1 to 8, wherein n is 2 at each occurrence.

10. The composition of any preceding claim, wherein the first compound and the second compound are present in equimolar amount.


11. The composition of any one of claims 4 to 10, wherein in formula (R-I):

the target binding moiety is configured to bind the IgG antibody so as to bring the reactive group in proximity with K246 or K248 of an IgG heavy chain of the IgG antibody to enable a reaction between K246 or K248 and the reactive group that results in attachment of a moiety comprising L^{RM}-MOI to K246 or K248 and expulsion of the group containing a target binding moiety from the compound.


12. The composition of claim 4, wherein the compound of formula (R-I) is selected from:




I-7;




I-8;




I-15;




I-19;



I-20;





I-23.

13. The composition of any preceding claim, wherein the IgG antibody is IVIG.